Olaparib and Veliparib can upregulate the expression of pro-apoptotic molecules Fas and death receptor 5 (DR5) on the surface of various cancer cells (leukemia, ovarian cancer, and lung cancer cells, etc.), making cancer cells more sensitive to TRAIL-induced apoptosis (149). Here, TNFRSF10B is linked to leukemia.